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Abstract
This study was performed to evaluate the effects of selenium supplementation on gene expression related to insulin and lipid
metabolism, and pregnancy outcomes in patients with gestational diabetes mellitus (GDM). The current randomized, double-
blind, placebo-controlled clinical trial was conducted in 36 patients with GDM. Participants were randomly divided into two
groups to intake either 200 μg/day selenium supplements as selenium yeast or placebo (n = 18 each group) for 6 weeks. Selenium
supplementation upregulated peroxisome proliferator-activated receptor gamma (P = 0.03) and glucose transporter 1 (GLUT-1)
(P = 0.01) in lymphocytes of subjects with GDM compared with the placebo. Selenium supplementation did not affect gene
expression of low-density lipoprotein receptor (LDLR) and lipoprotein(a) [Lp(a)]. Supplementation with selenium had a signif-
icant decrease in incidence of newborns’ hyperbilirubinemia (5.6% vs. 33.3%, P = 0.03) and newborns’ hospitalization (5.6% vs.
33.3%, P = 0.03) compared with the placebo. Overall, we found that selenium supplementation for 6 weeks among patients with
GDM significantly increased PPAR-γ and GLUT-1 expression, but did not affect gene expression of LDLR and LP(a). It also
reduced incidence of newborns’ hyperbilirubinemia and newborns’ hospitalization. Clinical trial registration number: http://
www.irct.ir: IRCT20170513033941N35.
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Introduction
Gestational diabetes mellitus (GDM) is defined as newly rec-
ognized diabetes during pregnancy that is not clearly existed
before [1]. It is a common endocrine disorder occurred in
pregnant women. According to the epidemiological studies,
the highest prevalence of GDM regardless of screening
criteria belongs to East-Asia with a range of 11.1–11.7% and
the lowest prevalence is attributed to Australia with a range of
3.6–3.7% [2]. Numerous evidence demonstrated that women
with GDM have an elevated future risk of type 2 diabetes
mellitus and cardiovascular disease [3]. Moreover, GDM is
illustrated to be associated with increased risk of obstetrical
consequences such as cesarean section, macrosomia, shoulder
dystocia, birth injury, and prematurity [4]. In long term, the
babies of mothers with GDM are prone to obesity and meta-
bolic disorders [5]. In GDMwomen, dietary modification and
glucose monitoring therapy as the primary therapeutic strategy
is reported to reduce the risk of several adverse outcomes,
including gestational hypertension and neonatal outcomes [6].
GDM is associated with lower selenium levels compared
with normal glucose tolerance pregnant women [7]. In addi-
tion, based on the results of several animal studies, selenium
deficiency is linked to altered expressed levels of genes related
to insulin signaling, inflammation, and lipid metabolism such
as peroxisome proliferator-activated receptor-γ (PPAR-γ) and
low-density lipoprotein receptor (LDLR) [8]. Some evidence
emphasize on the role of inappropriate mRNA transcript
levels of these genes and others involved in glucose and lipid
homeostasis in pregnancies complicated by GDM [9, 10].
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Previously, a meta-analysis indicated that selenium supple-
mentation improved insulin levels and insulin sensitivity in
patients with metabolic disorders, while did not affect other
measurement of glycemic control and serum lipids [11]. Few
studies have investigated the effects of selenium supplemen-
tation on expression levels of genes related to carbohydrate
and lipid metabolism. Earlier, we verified that an 8-week se-
lenium supplementation at a dosage of 200 μg/day to women
with polycystic ovary syndrome (PCOS) who were candidate
for in vitro fertilization (IVF) improved mRNA transcript
levels of PPAR-γ and glucose transporter 1 (GLUT-1), and
downregulated LDLR expression, while did not improve
lipoprotein(a) [LP(a)] expression [12]. There are several ani-
mal studies showing selenium administration improved gene
expression of GLUT-4, insulin receptor substrate-1 (IRS-1),
and PPAR-γ [13, 14]. In addition, some studies have been
conducted regarding the effectiveness of selenium supplemen-
tation on pregnancy complications. A meta-analysis conduct-
ed by Xu et al. [15] elucidated that selenium supplementation
to pregnant women significantly decreased the incidence of
preeclampsia. Moreover, it was observed that low selenium
status during pregnancy is associated with miscarriage [16]
and preterm delivery [17]. However, taking selenium supple-
ments at a dosage of 200 μg/day by HIV-infected pregnant
women between 12 and 27 weeks of gestation until 6 months
after delivery did not favorably influence pregnancy outcomes
[18].
Selenium is capable of alleviating inflammatory response
via the inhibition of nuclear factor kappa B (NF-κβ), toll-like
receptors (TLR), and mitogen-activated protein kinases
(MAPK) p38 pathways and bywhichmodulate the expression
levels of PPAR-γ and reduce insulin resistance [19]. In addi-
tion, it can counteract reactive oxygen species and free radi-
cals by its antioxidant activity and may reduce oxidative dam-
age associated with pregnancy [20]. Therefore, the present
study is aimed to examine the effects of selenium supplemen-
tation on gene expression related to insulin and lipid metabo-
lism, and pregnancy outcomes in GDM women.
Methods
Trial Design and Participants
This study, registered in the Iranian website for clinical trials
(http://www.irct.ir: IRCT20170513033941N35), was a
randomized, double-blind, placebo-controlled clinical trial.
The current study was conducted in 36 patients with GDM
class A1 that needed diet therapy at 24–28 weeks’ gestation
referred to the Akbarabadi Clinic in Tehran, Iran, between
July 2018 and March 2019. The investigation was performed
in accordance with the Declaration of Helsinki and informed
consent was taken from all participants. The study was
approved by the ethics committee of Iran University of
Medical Sciences (IUMS). Eligible subjects were primigravi-
da, aged 18–40 years who were diagnosed with GDM by a
“one-step” 2-h 75-g oral glucose tolerance test. Diagnosis of
GDMwas done based on the criteria of the AmericanDiabetes
Association [21]: those whose plasma glucose met one of the
following criteria were considered as having GDM: fasting ≥
92 mg/dL, 1-h ≥ 180 mg/dL, or 2-h ≥ 153 mg/dL. Subjects
with clinical characteristics at enrollment such as thyroid dis-
orders, smokers, preeclampsia, eclampsia, those with kidney
or liver diseases, and required commencing insulin therapy
during intervention, taking selenium supplements or other an-
tioxidants 3 months before the intervention were our exclu-
sion criteria.
Study Design
Participants were randomly allocated into two groups to re-
ceive either 200 μg selenium as selenium yeast free other
supplements such as zinc and copper (Nature Made,
California, USA) (n = 20) or placebo (Barij Essence,
Kashan, Iran) (n = 20) per day for 6 weeks. Selenium supple-
ments and placebos (cellulose) tablets were identical in shape
and size. Although the duration of intervention was 6 weeks,
all patients were followed up until the end of pregnancy.
Patients were requested not to change their routine physical
activity or usual diets throughout the study and not to take any
antioxidant medications or supplements that might affect their
nutritional status during the 6-week intervention.
Randomization assignment was conducted using computer-
generated random numbers. Allocation concealment and ran-
domization were conducted by the researchers and patients
and were done by a trained staff at the gynecology clinic.
Consumption of selenium supplements and placebos through-
out the study was checked through asking subjects to return
the medication containers. Furthermore, a short message was
sent to the cell phones of all patients every day to remind
participants to use the supplements. A 3-day food record at
weeks 0, 3, and 6 of the intervention was completed by all
participants using Nutritionist IV software (First Databank,
San Bruno, CA) modified for Iranian foods. A trained staff
at the clinic took anthropometric measurements at baseline
and after the 6-week intervention. Body weight was quantified
after an overnight fast using a digital scale (Seca, Hamburg,
Germany). Polyhydramnios was diagnosed using the sono-
graphic estimation method at end-of-trial. On the basis of this
measurement, polyhydramnios was defined as an amniotic
fluid index (AFI) in excess of 25 cm [22]. Newborns’
hyperbilirubinemia was considered when the total serum bil-
irubin levels were at 15 mg/dL or more among infants who
were 25 to 48 h old, 18 mg/dL in infants who were 49 to 72 h
old, and 20 mg/dL in infants older than 72 h [23].
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Assessment of Outcomes
Gene expression of PPAR-γ was considered as the primary
outcome and gene expression of GLUT-1, LDLR, LP(a), and
pregnancy outcomes was considered as the secondary
outcomes.
Isolation of Lymphocyte
At baseline and after the 6-week intervention, 15 mL fasting
blood samples were collected in the anticoagulant ethylenedi-
aminetetraacetic acid tubes. Then, lymphocytes were extract-
ed from blood samples of subjects with GDM at Akbarabadi
reference laboratory, Tehran, Iran, using 50% percoll solution
(Sigma-Aldrich, Dorset, UK) by centrifugation for 20min and
3000 rpm at 4 °C. The cells of lymphocytes which were at the
interface of percoll and serum were removed using a pasteur
pipette and washed a few times with phosphate buffer saline
[24]. Samples were taken for cell count and viability testing by
trypan blue, RNA, and DNA extraction [24].
Total RNA Extraction
To RNA extraction, the RNX-plus (Cinnacolon, Tehran, Iran)
was used. Total RNAwas isolated from all samples according
to recommended protocol bymanufacture. The total RNAwas
precipitated at room temperature for 15min. The pellet includ-
ing total RNAwas washed using 75% ethanol and centrifuge
at 7500g for 8 min. After drying ethanol, the RNA pellet
resuspended in 50 μl or less of TE buffer. The concentration
of total RNA was calculated based on OD 260/280 ration
measurements as a means to address purity of RNA [24].
Following the extraction of the total RNAs from each sample,
RNA quantification was performed by UV spectrophotome-
ter. Each sample OD 260/280 ratio between 1.7 and 2.1 was
intended that shows no contamination with both protein and
DNA [24]. The first-strand cDNA synthesis can be performed
as an individual reaction or as a series of parallel reactions
with different RNA templates [24]. The isolated RNA was
reverse transcribed to cDNA library using moloney murine
leukemia virus reverse transcriptase. Reverse transcription
was performed with random primers.
Gene Expression
Gene expression of PPAR-γ, GLUT-1, LDLR, and LP(a) was
evaluated by quantitative RT-PCR in lymphocytes, using the
LightCycler technology (Roche Diagnostics, Rotkreuz,
Switzerland) with SYBR green detection and Amplicon Kit
(Table 1). Glyceraldehyde-3-phosphate dehydrogenase
primers were applied as housekeeping gene. As template, ap-
proximately 50 ng cDNA was applied in a quantitative real-
time RT-PCR, and the signals were detected using a real-time
PCR system. To design primers, Primer Express Software
(Applied Biosystems, Foster City) and Beacon designer soft-
ware (Takaposizt, Tehran, Iran) were used. Relative transcrip-
tion values were calculated by the method of Pffafi.
Statistical Analyses
Using a formula suggested for clinical trials, having 17 sub-
jects in each group were adequate while considering a type
one error (α) of 0.05 and type two error (β) of 0.20 (power =
80%), 0.150-fold change as SD and 0.145-fold change as the
mean distinction (d) of gene expression of PPAR-γ as a pri-
mary outcome [12]. Assuming 20% dropouts in each group,
the final sample size was determined to be 20 patients in each
group.
To confirm whether the study variables had normally dis-
tributed or not, we used the Kolmogorov-Smirnov test. To
detect changes in anthropometric measures, dietary intakes,
gene expression related to insulin and lipid, and pregnancy
outcomes between the two groups, we used independent sam-
ples t test. The P value of < 0.05 was considered statistically
significant. All statistical analyses used the Statistical Package
for Social Science version 18 (SPSS Inc., Chicago, Illinois,
USA).
Results
Among individuals in the selenium and placebo groups, two
persons due to personal reasons were excluded (Fig. 1).
Finally, 36 participants (18 in each group) completed the trial.
The compliance rate in our study was high; participants re-
ported that more than 90% of selenium and placebo capsules
was consumed during the course of the trial. No side effects
were reported following the intake of selenium in patients
with GDM throughout the study.
Mean age, height, weight, and BMI at baseline as well as
mean weight and BMI after intervention were not statistically
different between the two groups (Table 1). Supplementation
with selenium had a significant decrease in incidence of new-
borns’ hyperbilirubinemia (5.6% vs. 33.3%, P = 0.03) and
newborns’ hospitalization (5.6% vs. 33.3%, P = 0.03) com-
pared with the placebo (Table 2). We did not find a significant
difference in polyhydramnios, gestational age, cesarean sec-
tion rate, need of insulin therapy after intervention, maternal
hospitalization, newborn’s birth size, and Apgar scores when
comparing the two groups (data not shown).
Based on the 3-day dietary records obtained throughout the
trial, we observed no significant change in dietary macro- and
micronutrient intakes (data not shown).
Selenium supplementation upregulated gene expression of
PPAR-γ (P = 0.03) and GLUT-1 (P = 0.01) in lymphocytes of
subjects with GDM (Fig. 2).
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Selenium supplementation did not affect gene expression
of LDLR (P = 0.64) and Lp(a) (P = 0.43) in lymphocytes of
subjects with GDM (Fig. 3).
Discussion
In the present study, we examined the effects of 6-week sele-
nium supplementation on gene expression related to insulin
and lipid metabolism, and pregnancy outcomes in women
with GDM. We found that selenium supplementation
significantly improved PPAR-γ and GLUT-1 expression, but
did not affect gene expression of LDLR and LP(a). It also
improved few pregnancy outcomes including newborns’
hyperbilirubinemia and newborns’ hospitalization.
Effects on Gene Expression
GDM is accompanied by disturbances inmaternal metabolism
which interference with the placental metabolism and affects
fetal outcomes [25]. The results of current study indicated that
selenium supplementation upregulated PPAR-γ and GLUT-1
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Fig. 1 Summary of patient flow diagram
Table 1 Specific primers used for
real-time quantitative PCR Gene Primer Product size (bp) Annealing temperature (°C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
PPAR-γ F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
GLUT-1 F: TATCTGAGCATCGTGGCCAT 238 62.1
R: AAGACGTAGGGACCACACAG
LDLR F: ACTTACGGACAGACAGACAG 223 57
R: GGCCACACATCCCATGATTC
Lp(a) F: GACACAGCACGTTCATTCCA 200 55
R: ACACCCCCCTACAATGCTTC
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLUT-1, glucose transporter 1; Lp(a), lipoprotein(a);
LDLR, low-density lipoprotein receptor; PPAR-γ, peroxisome proliferator-activated receptor gamma
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expression, while unchanged LDLR and LP(a) expression.
Consistent with the results of present study, a 16-week seleni-
um administration in mice led to an elevated gene expression
levels of PPAR-γ and GLUT-2 [13]. In addition, Xu et al. [26]
reported that a 4-week selenium supplementation (selenium
selenite) at a dosage of 180 μg/kg/day combined with low-
dose insulin improved blood glucose and HbA1c levels, and
increased gene expression of GLUT-4. Moreover, our previ-
ous research showed that 200 μg/day selenium supplementa-
tion for 8 weeks in women with PCOS candidate for IVF
upregulated mRNA transcript levels of PPAR-γ and GLUT-
1, and decreased LDLR, but did not affect gene expression of
LP(a) [12]. In contrast to our findings about the effects of
selenium supplementation on gene expression levels of
LP(a), an observational study by Alissa et al. [27], there was
a significant association between selenium status and serum
Lp(a) values in healthy adult males. Uncontrolled glucose and
lipid profiles in pregnant women are associated with adverse
clinical consequences for mother and infant [28]. PPAR-γ is a
member of a family of nuclear hormone receptors. Activation
of PPAR-γ involved in insulin sensitivity, glucose homeosta-
sis, lipid metabolism, adipogenesis, and inflammation [29].
Decreased circulating or mRNA transcript levels of PPAR-γ
have been implicated in pregnancies complicated by GDM,
preeclampsia, and intrauterine growth restriction. It has been
suggested that PPAR-γ may act as a regulator of maternal
metabolism and immune function in normal pregnancy. In
addition, due to the role in vascular function, it is essential
for the progression of a healthy pregnancy [30]. On the other
hand, animal studies indicated that GLUT-1 deficiency may
play a key role in the incidence of fetal malformations
resulting from the hyperglycemia of maternal diabetes [31].
Selenium supplementation inhibits the activity of NF-κβ,
TLR, and p38MAPK. It has been suggested that the inhibition
of these inflammatory pathways leads to an increase in gene
expression levels of PPAR-γ [19, 32]. In addition, GLUT-1
expression is inversely related to extracellular glucose concen-
trations [33]; therefore, the improvement of glucose homeo-
stasis by seleniummay be due to increased gene expression of
GLUT-1.
Effects on Pregnancy Outcomes
According to findings of present study, selenium supplemen-
tation in women with GDM led to a significant reduction in
newborns’ hyperbilirubinemia and newborns’ hospitalization.
Previously, it is reported that dietary selenium intake during
pregnancy was negatively correlated with indices of central
adiposity in neonate, while it was not associated with birth
weight [34]. In addition, 200 μg/day selenium supplementa-
tion in HIV-infected gestational women between 12 and
27 weeks of pregnancy until 6 months after delivery did not
improve preterm birth, newborns’ head circumference and
length, and other pregnancy complications [18]. In another
study by Bermudez et al. [35], selenium concentrations in
both umbilical cord and maternal blood were not related to
birth weight from small for gestational age to large for gesta-
tional age babies of healthymothers. In addition, in the present
study, we failed to find a significant effect of selenium sup-
plementation on the rate of preeclampsia in GDMmothers. In
contrast to our findings, a meta-analysis by Xu et al. [15]
indicated that selenium supplementation during pregnancy
decreased the risk of preeclampsia. Prior evidence demonstrat-
ed that macrosomia is associated with increased perinatal mor-
tality and neonatal morbidity. It also elevates the risk of cesar-
ean section, birth trauma, and shoulder dystocia [36]. Hence,
Table 2 General characteristics
of study participants and
pregnancy outcomes
Placebo group Selenium group P1
(n = 18) (n = 18)
Age (years) 29.5 ± 3.9 28.0 ± 4.1 0.26
Height (cm) 160.1 ± 3.2 162.1 ± 6.0 0.22
Weight at study baseline (kg) 67.4 ± 9.1 65.9 ± 11.0 0.68
Weight at end-of-trial (kg) 70.1 ± 9.3 68.5 ± 10.9 0.65
BMI at study baseline (kg/m2) 26.3 ± 3.4 25.1 ± 3.6 0.30
BMI at end-of-trial (kg/m2) 27.3 ± 3.4 26.0 ± 3.5 0.27
Pregnancy outcomes
Newborns’ weight (g) 3340.0 ± 462.4 3266.1 ± 436.3 0.62
Newborns’ length (cm) 51.3 ± 2.6 49.8 ± 4.0 0.20
Newborns’ head circumference (cm) 35.3 ± 1.3 35.0 ± 1.1 0.32
Newborns’ hyperbilirubinemia (%) 6 (33.3) 1 (5.6) 0.03†
Newborns’ hospitalization (%) 6 (33.3) 1 (5.6) 0.03†
Data are means ± SDs
1Obtained from independent t test
†Obtained from the Pearson chi-square test
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reduction in the risk of macrosomia is implicated in long-term
health of mother and infant. It is well established that maternal
metabolism is a major determinant of placental metabolism,
intrauterine environment, and fetal outcomes [25]. In pregnan-
cies affected by diabetes, maternal hyperglycemia and
hyperinsulinemia exacerbate the transfer of glucose to fetus
and increase fetal overgrowth. In addition, maternal diabetes
leads to several alternations in placenta structure and function
which ultimately change the nutrient delivery to fetus [37].
In the present study, we observed that selenium supplemen-
tation to pregnant women with GDM decreased the rate of
infant hyperbilirubinemia. It has been proposed that new-
borns’ hyperbilirubinemia may be a result of depleted antiox-
idant enzymes and increased oxidative stress during pregnan-
cy which increase radical generation and lipid peroxidation of
erythrocyte membrane which finally leads to hemolysis and
increased bilirubin levels in neonate [38]. Several studies re-
ported that selenium levels or other antioxidants in neonatal
with hyperbilirubinemia were significantly lower than the
control group [39, 40]. One mechanism regarding the poten-
tial role of selenium supplementation in reducing adverse
pregnancy outcomes such as infant hyperbilirubinemia is ex-
plained by its antioxidant activity which is applied through the
incorporation in the synthesis of glutathione peroxides,
selenoprotein P, and thioredoxin reductase [41].
The current study had a few limitations. Due to limited
funding, we did not evaluate the effects of selenium supple-
mentation on serum or urine selenium and glutathione perox-
idase. In addition, sample size was low. Further studies are
needed to confirm our findings with higher sample size.
Conclusions
Overall, we found that selenium supplementation significantly
increased PPAR-γ and GLUT-1 expression, but did not affect
gene expression of LDLR and LP(a). It also improved few
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pregnancy outcomes including newborns’ hyperbilirubinemia
and newborns’ hospitalization.
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